GNI GroupGNI Group Ltd.2160東証グロース医薬品FY ending Dec 2024, consolidated, IFRS

GNI Group FY ending Dec 2022 results

GNI Group brought in ¥17.4B in revenue.

Revenue changed +37.3% from the prior year.

What changed from last year

FY ending Dec 2021 → FY ending Dec 2022

FY ending Dec 2021 → FY ending Dec 2022

※ Cost of revenue is not disclosed; expenses are combined

※ Operating income is not disclosed; the chart goes straight to pretax income including investment gains

A machine-readable operating income value exists, but it is not in the validated published data, so the chart is omitted.

Show source documents (4)

EDINET (FSA Japan)
有価証券報告書－第25期(2025/01/01－2025/12/31)
ID S100XV4B2026-03-27Open
EDINET (FSA Japan)
有価証券報告書－第22期(2022/01/01－2022/12/31)
ID S100QIVF2023-03-31Open
EDINET (FSA Japan)
訂正有価証券報告書－第21期(令和3年1月1日－令和3年12月31日)
ID S100NYW82022-04-28Open
EDINET (FSA Japan)
有価証券報告書－第20期(令和2年1月1日－令和2年12月31日)
ID S100L3MC2021-03-31Open

Extracted from XBRL: 10 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.